Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 11 citations · 25 references
Life SciencesHematologyOncologyCancer GeneticsChemotherapyCytogeneticsCancer CytogeneticsClinical CytogeneticsHematologic Malignancy TherapyMolecular CytogeneticsAcute LeukemiasAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TreatmentComplex KaryotypesLeukemia CytogeneticsNumerical Chromosomal AbnormalitiesPrognostic Factors AnalysisTreatment Outcome Analysis
Monosomal karyotype (MK) and complex karyotype (CK) are poor prognostic factors in acute myeloid leukemia (AML). A comprehensive analysis of cytogenetic and clinical factors influencing an outcome of AML-CK+ was performed. The impact of cladribine containing induction on treatment results was also evaluated. We analyzed 125 patients with AML-CK+ treated within PALG protocols. MK was found in 75 (60%) individuals. The overall complete remission (CR) rate of 66 intensively treated patients was 62% vs. 28% in CK+ MK− and CK+ MK+ group (p = .01). No difference in CR rate was observed between DA and DAC arms. The overall survival (OS) in intensively treated patients was negatively influenced by MK, karyotype complexity (≥5 abnormalities), and WBC >20 G/L in multivariate analysis. The addition of cladribine to DA regimen improved OS only in MK− but not in MK+ group. In conclusion, concomitance of MK with ≥5 chromosomal abnormalities is associated with dismal treatment outcome in AMK-CK+.
25
David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · Blood · 2010 · 2K citations · Full text
Life Sciences, Hematology, Oncology +16
ISCN 1995 An international system for human cytogenetic nomenclature
Felix Mitelman · 1995 · 1.9K citations
Life Sciences, Biology, Genetics +10
John C. Byrd · Blood · 2002 · 1.6K citations
Medicine, Hematology, Oncology +16
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob Löwenberg, Gert J. Ossenkoppele, Wim van Putten et al. · New England Journal of Medicine · 2009 · 822 citations · Full text